The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
An overview of molecular hybrids in drug discovery
Open accessAbstract
INTRODUCTION: The hybridization of biologically active molecules is a powerful tool for drug discovery used to target a variety of diseases. It offers the prospect of better drugs for the treatment of a number of illnesses including cancer, malaria, tuberculosis and AIDS. Hybrid drugs can provide combination therapies in a single multi-functional agent and, by doing so, be more specific and powerful than conventional classic treatments. This research field is in great expansion and attracts many researchers worldwide. AREA COVERED: This review covers the main research published between early 2013 to mid-2015 and takes into account several previous reviews on the subject. Its intention is to showcase the most recent advances reported towards the development of molecular hybrids in drug discovery. Particular attention is given to anticancer hybrids throughout the review. EXPERT OPINION: Current advances show that molecular hybrids of biologically active molecules can lead to powerful therapeutics. Natural products play a key role in this field. It is also believed that toxin hybrids present a great opportunity for future progress and should be further explored. Furthermore, the synthesis of hybrid organometallics should be systematically studied as it can lead to potent drugs. The crucial requirement for growth still remains the efficacy of synthesis. Hence, the development of efficient synthetic methods allowing rapid access to diverse series of hybrids must be further investigated by researchers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent Advances in the Biginelli Dihydropyrimidine Synthesis. New Tricks from an Old Dog
Kappe, C. O. (2000) · Accounts of Chemical Research · doi:10.1021/ar000048h · Cited by 1,104
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
Deng, C., Wu, J., Cheng, R., Meng, F., Klok, H.-A., & Zhong, Z. (2014) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2013.10.008 · Cited by 371
Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends: Miniperspective
Zhan, P., Pannecouque, C., De Clercq, E., & Liu, X. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00497 · Cited by 303
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Advances in the development of hybrid anticancer drugs
Fortin, S., & Bérubé, G. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.798296 · Cited by 223
Self-citationMultifunctional compounds: Smart molecules for multifactorial diseases
Bansal, Y., & Silakari, O. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.060 · Cited by 212
Combination of ligand- and structure-based methods in virtual screening
Drwal, M. N., & Griffith, R. (2013) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2013.02.002 · Cited by 209
Taha, M., Ismail, N. H., Lalani, S., Fatmi, M. Q., Atia-tul-Wahab, Siddiqui, S., Khan, K. M., Imran, S., & Choudhary, M. I. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.009 · Cited by 165
Ma, L., Zheng, Y., Wang, S., Wang, B., Wang, Z.-R., Pang, L.-P., Zhang, M., Wang, J.-W., Ding, L., Li, J., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00037 · Cited by 165
Cited by
Shafiei, M., Peyton, L., Hashemzadeh, M., & Foroumadi, A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104240 · Cited by 295
Metadata
- Authors
- Bérubé, G.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa Healthcare
- Published
- 2016-01-12
- Volume
- 11
- Issue
- 3
- Pages
- 281-305
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W2255841639
- Cited by
- 338
- References
- 65
- FWCI
- 7.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An overview of molecular hybrids in drug discovery. https://app.cochat.ai/papers/10.1517/17460441.2016.1135125
- The paper
- Bérubé, G. (2016). An overview of molecular hybrids in drug discovery. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2016.1135125
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.